EGFR and lung carcinoma: In addition to the traditional lung cancer treatments of surgery, radiation and chemotherapy, molecularly targeted drugs such as EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) [3], and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (crizotinib) [4] have recently emerged as viable therapeutic options.